Clinical Trial Update: Gefitinib Combined With Thalidomide to Treat NSCLC [Phase 2, Phase 3]

View source ↗

Summary

Update on a phase 2/phase 3 clinical trial evaluating gefitinib in combination with thalidomide for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• Thalomid (thalidomide)

Snippet

Sponsor: Bai Jun | Conditions: NSCLC | Phase 2, Phase 3 | Status: UNKNOWN